Biologics Exclusivity: Key Questions Unlikely To Have Clear Answers From US FDA
Executive Summary
FDA’s embrace of biosimilars as part of the drug pricing response means a flurry of guidances coming soon. But don’t expect much clarity on key issues for innovators, like the boundaries of 12-year exclusivity and whether it will apply to NDA products that transition to BLAs, says a former CDER attorney.